[1]吴雨宸,王 俊,杨可夫.COPD患者血清GPR43、METTL3水平表达与肺功能和气流受限程度的相关性研究[J].现代检验医学杂志,2026,41(02):128-133.[doi:10.3969/j.issn.1671-7414.2026.02.022]
　WU Yuchen,WANG Jun,YANG Kefu.Study on the Correlation between Serum GPR43 and METTL3 Expression Levels and Pulmonary Function and Airflow Limitation in COPD Patients[J].Journal of Modern Laboratory Medicine,2026,41(02):128-133.[doi:10.3969/j.issn.1671-7414.2026.02.022]
点击复制

COPD患者血清GPR43、METTL3水平表达与肺功能和气流受限程度的相关性研究()

《现代检验医学杂志》[ISSN:/CN:]

卷:
第41卷
期数:
2026年02期
页码:
128-133
栏目:
论著
出版日期:
2026-03-15

文章信息/Info

Title:
Study on the Correlation between Serum GPR43 and METTL3 Expression Levels and Pulmonary Function and Airflow Limitation in COPD Patients
文章编号:
1671-7414（2026）02-128-06
作者:
吴雨宸a，王 俊a，杨可夫b
成都市第六人民医院 a.呼吸与危重症医学科；b.检验科，成都 610051
Author(s):
WU Yuchena, WANG Juna, YANG Kefub
a. Department of Respiratory and Critical Care Medicine; b. Department of Clinical Laboratory, Chengdu Sixth People’s Hospital, Sichuan Chengdu 610051, China
关键词:
慢性阻塞性肺疾病; G蛋白偶联受体43; 甲基转移酶3; 肺功能; 气流受限程度
分类号:
R563；R446.11
DOI:
10.3969/j.issn.1671-7414.2026.02.022
文献标志码:
A
摘要:
目的?探讨慢性阻塞性肺疾病(COPD)患者血清G蛋白偶联受体43(GPR43)、甲基转移酶3(METTL3)水平表达与肺功能和气流受限程度的相关性。方法选取2019年1月~2024年5月成都市第六人民医院收治的COPD患者150例(COPD组)和同期健康体检志愿者150例(对照组)。根据气流受限程度将COPD患者分为轻度组(n=61)、中度组(n=46)和重度/极重度组(n=43)。检测血清GPR43、METTL3水平并测定肺功能[第1秒用力呼气容积(FEV1)/用力肺活量(FVC)、FEV1占预计值%(%pred)]。Spearman相关性分析血清GPR43、METTL3水平与肺功能指标的相关性;通过多元有序Logistic回归分析血清GPR43、METTL3水平与COPD患者气流受限程度的关系,使用受试者工作特征(ROC)曲线分析其评估效能。结果与对照组比较,COPD组血清GPR43水平(5.32±1.07ng/mlvs7.61±1.59ng/ml),FEV1/FVC比值[54.17(43.77,63.60)%vs80.78(76.24,88.22)%]和FEV1%pred[72.25(44.94,84.22)%vs93.06(89.71、95.54)%]显著降低(t/Z=-14.591,-14.247,-14.108),而METTL3水平(41.73±5.27pg/mlvs31.85±5.03pg/ml)显著升高(t=16.614),差异具有统计学意义(均P<0.001)。重度/极重度组血清GPR43水平低于轻度、中度组(4.57±0.77ng/mlvs5.98±1.05ng/ml、5.16±0.79ng/ml),中度组低于轻度组(t=7.474、3.598、4.391),重度/极重度组血清METTL3水平高于轻度组、中度组(45.76±5.24pg/mlvs38.83±4.20pg/ml、41.82±4.00pg/ml),中度组高于轻度组(t=-7.474、-4.003、-3.722),差异具有统计学意义(均P<0.001)。COPD患者FEV1/FVC比值、FEV1%pred与血清GPR43水平呈正相关(r=0.762、0.768,均P<0.001),与METTL3水平呈负相关(r=-0.758、-0.778,均P<0.001)。GPR43为COPD气流受限的独立保护因素(OR=0.689,Waldχ2=14.064,P<0.05),METTL3为独立危险因素(OR=1.251,Waldχ2=4.500,P<0.05)。血清GPR43与METTL3联合评估COPD重度/极重度气流受限的曲线下面积(AUC)优于GPR43和METTL3单独检测,差异具有统计学意义(Z=3.231、3.374,均P<0.05)。结论COPD患者血清GPR43水平降低、METTL3水平升高,与肺功能降低和气流受限程度加重有关,血清GPR43,MET-TL3水平联合评估COPD患者重度/极重度气流受限的价值较高。
Abstract:
Objective To explore the correlation between serum levels of G protein-coupled receptor 43 (GPR43) and methyl-transferase 3 (METTL3), pulmonary function and the degree of airflow limitation in patients with chronic obstructive pulmonary disease (COPD). Methods A total of 150 COPD patients (COPD group) admitted to Chengdu Sixth People's Hospital from Janu-ary 2019 and May 2024 and 150 healthy volunteers undergoing physical examinations during the same period (control group) were enrolled. COPD patients were classified into mild (n=61), moderate (n=46), and severe/very severe (n=43) groups based on the degree of airflow limitation. Serum GPR43 and METTL3 levels were measured, and pulmonary function parameters [forced expiratory volume in 1 second (FEV1)/forced vital capacity (FVC), FEV1 as a percentage of predicted value (%pred)] was as-sessed. Spearman correlation analysis was used to assess the relationship between serum GPR43 and METTL3 levels and pulmo-nary function indicators. Multivariate ordered Logistic regression was used to analyze the relationship between serum GPR43 and METTL3 levels and the degree of airflow limitation in COPD patients. Receiver operating characteristic (ROC) curve analysis was used to evaluate their diagnostic efficacy. Results Compared to the control group, the COPD group had significantly lower serum GPR43 levels (5.32±1.07 ng/ml vs 7.61±1.59 ng/ml), FEV1/FVC ratio [54.17 (43.77, 63.60) % vs 80.78 (76.24, 88.22) %], and FEV1 % predicted [72.25 (44.94, 84.22) % vs 93.06 (89.71, 95.54) %], while METTL3 levels were significantly higher (41.73±5.27 pg/ml vs 31.85±5.03 pg/ml) (t=16.614, all P<0.001). Serum GPR43 levels decreased progressively across mild, moderate and severe/very severe groups (4.57±0.77ng/ml vs 5.98±1.05 ng/ml, 5.16±0.79 ng/ml), while METTL3 levels increased (45.76±5.24 pg/ml vs 38.83±4.20 pg/ml, 41.82±4.00 pg/ml), with statistically significant differences (tGPR43=7.474, 3.598, 4.391;tMETTL3=-7.474,-4.003,-3.722, all P<0.001). In COPD patients, FEV1/FVC ratio and FEV1%pred were positively correlated with se-rum GPR43 levels (r=0.762, 0.768, all P<0.001) and negatively correlated with METTL3 levels (r=-0.758, -0.778, all P<0.001). GPR43 was an independent protective factor for airflow limitation in COPD (OR=0.689, Wald χ2=14.064, P<0.05), while METTL3 was an independent risk factor (OR=1.251, Wald χ2=4.500, P<0.05). The combined assessment of serum GPR43 and METTL3 levels for evaluating severe/very severe airflow limitation in COPD patients had an area under the curve (AUC) superior to using GPR43 or MET-TL3 alone (Z=3.231, 3.374, all P<0.05). Conclusions In COPD patients, decreased serum GPR43 and elevated METTL3 levels are as-sociated with impaired lung function and worsening airflow limitation. The combined assessment of serum GPR43 and METTL3 levels shows high value in assessing severe/very severe airflow limitation in COPD patients.

参考文献/References:

[1] 中华医学会,中华医学会杂志社,中华医学会全科医学分会,等.中国慢性阻塞性肺疾病基层诊疗与管理指南(2024年)[J].中华全科医师杂志,2024,23(6):578-602. Chinese Medical Association, Chinese Medical Asso-ciation Publishing House,Chinese Society of General Practice, et al. Chinese guideline for management of chronic obstructive pulmonary disease in primary care(2024)[J]. Chinese Journal of General Practitioners, 2024, 23(6): 578-602.
[2] 王文星,王璐,邬超,等.1990-2019年中国慢性阻塞性肺疾病的疾病负担分析及未来10年发病预测[J].新疆医科大学学报,2024,47(1):135-140. WANG W X, WANG L, WU C, et al. Disease bur-den analysis of chronic obstructive pulmonary dis-ease(COPD)in China from 1990 to 2019 and incidence prediction in the next 10 years[J]. Journal of Xinjiang Medical University, 2024, 47(1): 135-140.
[3] 吴家明,刘韫,周德伟.慢性阻塞性肺疾病急性加重期患者血清FIZZ2和IL-33水平变化与临床预后的相关性研究[J].现代检验医学杂志,2024,39(5):140-145. WU J M, LIU Y, ZHOU D W. Changes of serum FIZZ2 and IL-33 levels in patients with acute exacerbation of chronic obstructive pulmonary disease and their cor-relation with clinical prognosis[J]. Journal of Modern Laboratory Medicine, 2024, 39(5): 140-145.
[4] 《慢性阻塞性肺疾病免疫调节治疗专家共识》撰写组.慢性阻塞性肺疾病免疫调节治疗专家共识[J].中国全科医学,2022,25(24):2947-2959. Writing Group for the Expert Consensus on Immuno-modulatory Therapies for Chronic Obstructive Pulmo-nary Disease. Expert consensus on immunomodulatory therapies for chronic obstructive pulmonary disease[J]. Chinese General Practice, 2022, 25(24): 2947-2959.
[5] LEE D H , KIM M T , HAN J H .GPR41 and GPR43:from development to metabolic regulation[J].Biomedi-cine & Pharmacotherapy, 2024, 175: 116735.
[6] MAO J, LI Y, BIAN Q Q, et al. The Bufei Jianpi for-mula improves mucosal immune function by remodel-ing gut microbiota through the SCFAs/GPR43/NLRP3 pathway in chronic obstructive pulmonary disease rats[J]. International Journal of Chronic Obstructive Pulmonary Disease, 2022, 17: 1285-1298.
[7] ZHANG D S, GOU Z X, QU Y, et al. Understanding how methyltransferase-like 3 functions in lung diseas-es: from pathogenesis to clinical application [J]. Bio-medicine & Pharmacotherapy, 2024, 179: 117421.
[8] HUANG X W, L? D J, YANG X, et al. M6A RNA methylation regulators could contribute to the occur-rence of chronic obstructive pulmonary disease[J]. Journal of Cellular and Molecular Medicine, 2020, 24(21): 12706-12715.
[9] 中华医学会,中华医学会杂志社,中华医学会全科医学分会,等.慢性阻塞性肺疾病基层诊疗指南(2018年)[J].中华全科医师杂志,2018,17(11):856-870. Chinese Medical Association, Chinese Medical Journals Publishing House,Chinese Society of General Practice, et al. Guideline for primary care of chronic obstructive pulmonary disease (2018)[J]. Chinese Journal of Gen-eral Practitioners, 2018, 17(11): 856-870.
[10] Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management and prevention of chronic obstructive lung disease(2018 report) [EB/OL](2024-11-01). https://goldcopd.org/wp-content/uploads/2017/11/GOLD-2018-v6.0-FI-NAL-revised-20-Nov_WMS.pdf.
[11] 中华医学会呼吸病学分会慢性阻塞性肺疾病学组,中国医师协会呼吸医师分会慢性阻塞性肺疾病工作委员会.慢性阻塞性肺疾病诊治指南(2021年修订版) [J].中华结核和呼吸杂志,2021,44(3):170-205. Chronic Obstructive Pulmonary Disease Group of Chi-nese Thoracic Society,Chronic Obstructive Pulmonary Disease Committee of Chinese Association of Chest Physician. Guidelines for the diagnosis and manage-ment of chronic obstructive pulmonary disease (revised version 2021)[J]. Chinese Journal of Tuberculosis and Respiratory Diseases, 2021, 44(3): 170-205.
[12] 周丽娟,温贤秀,吕琴,等.使用机器学习建立慢性阻塞性肺疾病患者重度气流受限风险预警模型研究[J].中国全科医学,2022,25(2):217-226. ZHOU L J, WEN X X, L? Q, et al. Using machine learning to build an early warning model for the risk of severe airflow limitation in patients with chronic ob-structive pulmonary disease[J]. Chinese General Prac-tice, 2022, 25(2): 217-226.
[13] DONG L L, LIU Z Y, CHEN K J, et al. The persistent inflammation in COPD: is autoimmunity the core mechanism?[J]. European Respiratory Review, 2024,33(171): 230137.
[14] AL MAHRI S, MALIK S S, AL IBRAHIM M, et al. Free fatty acid receptors (FFARs) in adipose: physi-ological role and therapeutic outlook[J]. Cells, 2022, 11(4): 750.
[15] XU Q M, XU J Y, WU Y F. Regulation of inflammation and apoptosis by GPR43 via JNK/Elk1 in acute lung injury[J]. Inflammation Research, 2022, 71(5/6): 603-614.
[16] ZHANG W W, WANG W S, XU M D, et al. GPR43 regulation of mitochondrial damage to alleviate in-flammatory reaction in sepsis [J]. Aging (Albany NY), 2021, 13(18): 22588-22610.
[17] ZHAO Z J, TONG Y Q, KANG Y T. Sodium butyrate (SB) ameliorated inflammation of COPD induced by cigarette smoke through activating the GPR43 to inhibit NF-κB/MAPKs signaling pathways[J].Molecular Im-munology, 2023, 163 : 224-234.
[18] 何佳英,罗曼,雷翊柔,等.肠道菌群在慢性阻塞性肺疾病中研究进展[J].临床肺科杂志,2023,28(11):1736-1739. HE J Y, LUO M, LEI Y R, et al. Progress of intesti-nal flora in chronic obstructive pulmonary disease[J]. Journal of Clinical Pulmonary Medicine, 2023, 28(11):1736-1739.
[19] 李海博,杨静帆,秦燕勤,等.N6-腺苷酸甲基化修饰在呼吸系统疾病发生发展中作用的研究进展[J].中华危重病急救医学,2024,36(3):303-307. LI H B, YANG J F, QIN Y Q, et al. Research progress on the role of N6-methyladenosine methylation in the pathogenesis and development of respiratory diseas-es[J]. Chinese Critical Care Medicine, 2024, 36(3):303-307.
[20] CHEN P, LIU J W, SUN K N, et al. Methylation of TTC4 interaction with HSP70 inhibits pyroptosis in macrophages of sepsis-induced lung injury by NLRP3 inflammation[J]. American Journal of Cancer Research, 2023, 13(11): 5122-5137.
[21] XU S N, XING J, ZHENG L, et al. Azithromycin reg-ulates METTL3-mediated NF-κB pathway to enhance M2 polarization of RAW264.7 macrophages and atten-uate LPS-triggered cytotoxicity of MLE-12 alveolar cells [J]. International Immunopharmacology, 2024, 137: 112426.
[22] WANG L J, YU Q, XIAO J, et al. Cigarette smoke extract-treated mouse airway epithelial cells-derived exosomal lncRNA MEG3 promotes M1 macrophage polarization and pyroptosis in chronic obstructive pulmonary disease by upregulating TREM-1 via m6A methylation[J]. Immune Network, 2024, 24(2): e3.
[23] ZHANG Y P, WANG L X, YAN F R, et al. METTL3 mediated m6A methylation involved in epithelial-mes-enchymal transition by targeting SOCS3/STAT3/SNAI1 in cigarette smoking-induced COPD[J]. International Journal of Chronic Obstructive Pulmonary Disease, 2023, 18: 1007-1017.

相似文献/References:

[1]邱淑佳.慢性阻塞性肺疾病患者血清LCN1,LCN2的表达水平及临床意义[J].现代检验医学杂志,2017,32(06):67.[doi:10.3969/j.issn.1671-7414.2017.06.001]
　QIU Shu-jia.Expression Levels of Serum LCN1 and LCN2 in Patients with Acute Exacerbation of Chronic Obstructive Pulmonary Disease and Its Clinical Significance[J].Journal of Modern Laboratory Medicine,2017,32(02):67.[doi:10.3969/j.issn.1671-7414.2017.06.001]
[2]杜 洁,朱 娜,李红艳,等.幽门螺杆菌感染对慢性阻塞性肺疾病血气分析及肺功能的影响[J].现代检验医学杂志,2017,32(06):99.[doi:10.3969/j.issn.1671-7414.2017.06.001]
　DU Jie,ZHU Na,LI Hong-yan,et al.Effect of Helicobacter Pylori Infection on Blood Gas Analysis and Pulmonary Function in Patients with Chronic Obstructive Pulmonary Disease[J].Journal of Modern Laboratory Medicine,2017,32(02):99.[doi:10.3969/j.issn.1671-7414.2017.06.001]
[3]李若倩,刘　云,李若然.外周血红细胞分布宽度和超敏C- 反应蛋白水平检测在慢性阻塞性肺疾病诊断中的价值分析[J].现代检验医学杂志,2020,35(03):123.[doi:10.3969/j.issn.1671-7414.2020.03.033]
　LI Ruo-qian,LIU Yun,LI Ruo-ran.Value of Detecting Peripheral Blood Red Blood Cell Distribution Width and High Sensitivity C Reactive Protein in the Diagnosis of Chromic Obstructive Pulmonary Disease[J].Journal of Modern Laboratory Medicine,2020,35(02):123.[doi:10.3969/j.issn.1671-7414.2020.03.033]
[4]陈元菁,艾红军,王湘云,等.COPD 患者线粒体功能及代谢水平变化检测与骨骼肌功能障碍的相关性研究[J].现代检验医学杂志,2020,35(06):25.[doi:doi:10.3969/j.issn.1671-7414.2020.06.007]
　CHEN Yuan-jing,AI Hong-jun,WANG Xiang-yun,et al.Study on the Correlation between Changes Detection in Mitochondrial Function,Metabolic Level and Skeletal Muscle Dysfunction Inpatients with COPD[J].Journal of Modern Laboratory Medicine,2020,35(02):25.[doi:doi:10.3969/j.issn.1671-7414.2020.06.007]
[5]王　苗,张　萍.COPD患者血清 Cav-1及 CXCL12水平检测与并发肺动脉高压的相关性研究[J].现代检验医学杂志,2021,36(01):29.[doi:10.3969/j.issn.1671-7414.2021.01.008]
　WANG Miao,ZHANG Ping.Correlation between Levels of Cav-1 and CXCL12 in Serum and Pulmonary Hypertension in Patients with COPD[J].Journal of Modern Laboratory Medicine,2021,36(02):29.[doi:10.3969/j.issn.1671-7414.2021.01.008]
[6]闫海燕,杨云秀,杨云华,等.慢性阻塞性肺疾病患者 Nrf2 基因多态性与肺功能及临床病情判断的相关性研究[J].现代检验医学杂志,2021,36(03):27.[doi:10.3969/j.issn.1671-7414.2021.03.007]
　YAN Hai-yan1,YANG Yun-xiu2,YANG Yun-hua3,et al.Study on Relevance of Nrf2 Gene Polymorphism with Pulmonary Functionand Clinical Condition Judgment in Patients with Chronic ObstructivePulmonary Disease[J].Journal of Modern Laboratory Medicine,2021,36(02):27.[doi:10.3969/j.issn.1671-7414.2021.03.007]
[7]胡小燕,郑　晓,嵇华夏,等.血清 PCT 与 BNP 水平联合检测对慢性阻塞性肺疾病急性加重期并发心力衰竭的临床诊断价值[J].现代检验医学杂志,2021,36(03):128.[doi:10.3969/j.issn.1671-7414.2021.03.029]
　HU Xiao-yan,ZHENG Xiao,JI Hua-xia,et al.Clinical Diagnostic Value of Combined Detection of Serum PCT and BNPLevels in Patients with Acute Exacerbation of Chronic Obstructive Pulmonary Disease Complicated with Heart Failure[J].Journal of Modern Laboratory Medicine,2021,36(02):128.[doi:10.3969/j.issn.1671-7414.2021.03.029]
[8]陈志勇,罗世林,张　健,等.慢阻肺患者血清IL-17，IL-27和IL-33水平表达及与不同临床分期FeNO和肺功能的相关性研究[J].现代检验医学杂志,2021,36(04):152.[doi:10.3969/j.issn.1671-7414.2021.04.033]
　CHEN Zhi-yong,LUO Shi-lin,ZHANG Jian,et al.Expression of Serum IL-17, IL-27 and IL-33 in Patients with ChronicObstructive Pulmonary Disease and Its Correlation with FeNO and LungFunction in Different Clinical Stages[J].Journal of Modern Laboratory Medicine,2021,36(02):152.[doi:10.3969/j.issn.1671-7414.2021.04.033]
[9]王述红,邱　容,罗晓斌,等.慢性阻塞性肺疾病患者血气分析指标，FeNO，EOS%水平变化与CAT评分的相关性研究[J].现代检验医学杂志,2021,36(04):156.[doi:10.3969/j.issn.1671-7414.2021.04.034]
　WANG Shu-hong,QIU Rong,LUO Xiao-bin,et al.Correlation between Changes of Blood Gas Analysis Indexes, FeNO, EOS%and CAT Score in Patients with Chronic Obstructive Pulmonary Disease[J].Journal of Modern Laboratory Medicine,2021,36(02):156.[doi:10.3969/j.issn.1671-7414.2021.04.034]
[10]龙借帆,李　翠,高元标,等.联合检测血清SIRT1和CTRP5水平对慢性阻塞性肺疾病急性加重期患者预后的预测价值研究[J].现代检验医学杂志,2022,37(03):162.[doi:10.3969/j.issn.1671-7414.2022.03.034]
　LONG Jie-fan,LI Cui,GAO Yuan-biao,et al.Prognostic Value of Combined Detection of Serum SIRT1 and CTRP5 Levels in Patients with Acute Exacerbation of Chronic Obstructive Pulmonary Disease[J].Journal of Modern Laboratory Medicine,2022,37(02):162.[doi:10.3969/j.issn.1671-7414.2022.03.034]

备注/Memo

备注/Memo:
基金项目：四川省医学科研课题项目（编号：S19022）。
作者简介：吴雨宸（1990-），女，本科，主治医师，研究方向：慢性阻塞性肺疾病，E-mail：Wyc2589630@163.com。
更新日期/Last Update: 2026-03-15